WCM Investment Management LLC lifted its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 99.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,116 shares of the company's stock after acquiring an additional 1,053 shares during the period. WCM Investment Management LLC's holdings in Cencora were worth $476,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in COR. Dynamic Advisor Solutions LLC boosted its stake in Cencora by 15.2% during the third quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company's stock valued at $262,000 after buying an additional 154 shares during the last quarter. Valeo Financial Advisors LLC boosted its stake in Cencora by 5.0% during the third quarter. Valeo Financial Advisors LLC now owns 1,645 shares of the company's stock valued at $370,000 after buying an additional 79 shares during the last quarter. Gateway Investment Advisers LLC boosted its stake in Cencora by 9.0% during the third quarter. Gateway Investment Advisers LLC now owns 4,388 shares of the company's stock valued at $988,000 after buying an additional 364 shares during the last quarter. Retirement Planning Group LLC bought a new position in Cencora during the third quarter valued at approximately $251,000. Finally, Exchange Traded Concepts LLC boosted its stake in Cencora by 41.6% during the third quarter. Exchange Traded Concepts LLC now owns 5,334 shares of the company's stock valued at $1,201,000 after buying an additional 1,568 shares during the last quarter. 97.52% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 21,509 shares of the firm's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the transaction, the chairman now owns 306,752 shares in the company, valued at $74,283,064.32. The trade was a 6.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,187 shares of company stock worth $17,790,912 in the last ninety days. 10.80% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on COR. Evercore ISI increased their price target on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Barclays raised their price objective on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Mizuho assumed coverage on Cencora in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price objective for the company. Finally, Robert W. Baird raised their price objective on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Cencora currently has an average rating of "Moderate Buy" and an average price target of $277.90.
View Our Latest Research Report on COR
Cencora Trading Down 0.6 %
Shares of NYSE COR traded down $1.50 during midday trading on Friday, hitting $243.03. The company's stock had a trading volume of 1,277,896 shares, compared to its average volume of 1,517,200. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40. The business's 50 day moving average is $238.70 and its two-hundred day moving average is $237.38. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26. The firm has a market cap of $46.97 billion, a P/E ratio of 34.57, a price-to-earnings-growth ratio of 1.49 and a beta of 0.49.
Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities research analysts expect that Cencora, Inc. will post 15.36 EPS for the current year.
Cencora Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be issued a dividend of $0.55 per share. The ex-dividend date is Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.91%. Cencora's payout ratio is currently 31.29%.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
See Also
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
